David T. Okou

David T. Okou

Auto-generated profile, based on publicly available information

David T. Okou

Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2007 in Nature Methods
Verified
Journal Article
Closed access
PDF file
DODavid T Okou
David T Okou
KSKaryn Meltz Steinberg
Karyn Meltz Steinberg
CMChristina Middle
Christina Middle
DCDavid J Cutler
David J Cutler
TAThomas J Albert
Thomas J Albert
MZMichael E Zwick
Michael E Zwick

15 May 2009 in Journal of Bacteriology
Verified
Journal Article
Closed access
KPKarla D. Passalacqua
Karla D. Passalacqua
AVAnjana Varadarajan
Anjana Varadarajan
BOBrian D. Ondov
Brian D. Ondov
DODavid T. Okou
David T. Okou
MZMichael E. Zwick
Michael E. Zwick
NBNicholas H. Bergman
Nicholas H. Bergman
Although gene expression has been studied in bacteria for decades, many aspects of the bacterial transcriptome remain poorly understood. Transcript structure, operon linkages, and information on absolute abundance all provide valuable insights into gene function and regulation, but none has ever been determined on a genome-wide scale for any bacterium. Indeed, these aspects of the prokaryotic transcriptome have been explored on a large scale in only a few instances, and consequently little is known about the absolute composition of the mRNA population within a bacterial cell. Here we report the use of a high-throughput sequencing-based approach in assembling the first comprehensive, single-nucleotide resolution view of a bacterial transcriptome. We sampled the Bacillus anthracis transcriptome under a variety of growth conditions and showed that the data provide an accurate and high-resolution map of transcript start sites and operon structure throughout the genome. Further, the sequence data identified previously nonannotated regions with significant transcriptional activity and enhanced the accuracy of existing genome annotations. Finally, our data provide estimates of absolute transcript abundance and suggest that there is significant transcriptional heterogeneity within a clonal, synchronized bacterial population. Overall, our results offer an unprecedented view of gene expression and regulation in a bacterial cell.

1 January 2017 in Gastroenterology
Verified
Journal Article
Open access
PDF file
SBSteven R. Brant
Steven R. Brant
DODavid T. Okou
David T. Okou
CSClaire Simpson
Claire Simpson
DCDavid J. Cutler
David J. Cutler
THTalin Haritunians
Talin Haritunians
SKSubra Kugathasan
Subra Kugathasan
Background & Aims The inflammatory bowel diseases (IBD) ulcerative colitis (UC) and Crohn’s disease (CD) cause significant morbidity and are increasing in prevalence among all populations, including African Americans. More than 200 susceptibility loci have been identified in populations of predominantly European ancestry, but few loci have been associated with IBD in other ethnicities. Methods We performed 2 high-density, genome-wide scans comprising 2345 cases of African Americans with IBD (1646 with CD, 583 with UC, and 116 inflammatory bowel disease unclassified) and 5002 individuals without IBD (controls, identified from the Health Retirement Study and Kaiser Permanente database). Single-nucleotide polymorphisms (SNPs) associated at P < 5.0 × 10−8 in meta-analysis with a nominal evidence (P < .05) in each scan were considered to have genome-wide significance. Results We detected SNPs at HLA-DRB1, and African-specific SNPs at ZNF649 and LSAMP, with associations of genome-wide significance for UC. We detected SNPs at USP25 with associations of genome-wide significance for IBD. No associations of genome-wide significance were detected for CD. In addition, 9 genes previously associated with IBD contained SNPs with significant evidence for replication (P < 1.6 × 10−6): ADCY3, CXCR6, HLA-DRB1 to HLA-DQA1 (genome-wide significance on conditioning), IL12B, PTGER4, and TNC for IBD; IL23R, PTGER4, and SNX20 (in strong linkage disequilibrium with NOD2) for CD; and KCNQ2 (near TNFRSF6B) for UC. Several of these genes, such as TNC (near TNFSF15), CXCR6, and genes associated with IBD at the HLA locus, contained SNPs with unique association patterns with African-specific alleles. Conclusions We performed a genome-wide association study of African Americans with IBD and identified loci associated with UC in only this population; we also replicated IBD, CD, and UC loci identified in European populations. The detection of variants associated with IBD risk in only people of African descent demonstrates the importance of studying the genetics of IBD and other complex diseases in populations beyond those of European ancestry.

28 July 2008 in Human Mutation
Verified
Journal Article
Open access
PDF file
MHMadhuri R. Hegde
Madhuri R. Hegde
ECEphrem L.H. Chin
Ephrem L.H. Chin
JMJennifer G. Mulle
Jennifer G. Mulle
DODavid T. Okou
David T. Okou
SWStephen T. Warren
Stephen T. Warren
MZMichael E. Zwick
Michael E. Zwick
Duchenne and Becker muscular dystrophies (DMD and BMD) are X‐linked recessive neuromuscular disorders caused by mutations in the dystrophin gene affecting approximately 1 in 3,500 males. The human dystrophin gene spans>2,200 kb, or roughly 0.1% of the genome, and is composed of 79 exons. The mutational spectrum of disease‐causing alleles, including exonic copy number variations (CNVs), is complex. Deletions account for approximately 65% of DMD mutations and 85% of BMD mutations. Duplications occur in approximately 6 to 10% of males with either DMD or BMD. The remaining 30 to 35% of mutations consist of small deletions, insertions, point mutations, or splicing mutations, most of which introduce a premature stop codon. Laboratory analysis of dystrophin can be used to confirm a clinical diagnosis of DMD, characterize the type of dystrophin mutation, and perform prenatal testing and carrier testing for females. Current dystrophin diagnostic assays involve a variety of methodologies, including multiplex PCR, Southern blot analysis, multiplex ligation‐dependent probe amplification (MLPA), detection of virtually all mutations‐SSCP (DOVAM‐S), and single condition amplification/internal primer sequencing (SCAIP); however, these methods are time‐consuming, laborious, and do not accurately detect duplication mutations in the dystrophin gene. Furthermore, carrier testing in females is often difficult when a related affected male is unavailable. Here we describe the development, design, validation, and implementation of a high‐resolution comparative genomic hybridization (CGH) microarray‐based approach capable of accurately detecting both deletions and duplications in the dystrophin gene. This assay can be readily adopted by clinical molecular testing laboratories and represents a rapid, cost‐effective approach for screening a large gene, such as dystrophin. Hum Mutat 0, 1–9, 2008.

1 October 2001 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
CCCheng-Feng Chiang
Cheng-Feng Chiang
DODavid T. Okou
David T. Okou
TGTony B. Griffin
Tony B. Griffin
CVC.Reynold Verret
C.Reynold Verret
MWMyron N.V. Williams
Myron N.V. Williams

1 November 2015 in Gastroenterology
Verified
Journal Article
Open access
PDF file
CHChengrui Huang
Chengrui Huang
THTalin Haritunians
Talin Haritunians
DODavid T. Okou
David T. Okou
DCDavid J. Cutler
David J. Cutler
MZMichael E. Zwick
Michael E. Zwick
SKSubra Kugathasan
Subra Kugathasan
Inflammatory bowel disease (IBD) has familial aggregation in African Americans (AAs), but little is known about the molecular genetic susceptibility. Mapping studies using the Immunochip genotyping array expand the number of susceptibility loci for IBD in Caucasians to 163, but the contribution of the 163 loci and European admixture to IBD risk in AAs is unclear. We performed a genetic mapping study using the Immunochip to determine whether IBD susceptibility loci in Caucasians also affect risk in AAs and identify new associated loci. We recruited AAs with IBD and without IBD (controls) from 34 IBD centers in the United States; additional controls were collected from 4 other Immunochip studies. Association and admixture loci were mapped for 1088 patients with Crohn’s disease, 361 with ulcerative colitis, 62 with IBD type unknown, and 1797 controls; 130,241 autosomal single-nucleotide polymorphisms (SNPs) were analyzed. The strongest associations were observed between ulcerative colitis and HLA rs9271366 (P = 7.5 × 10−6), Crohn’s disease and 5p13.1 rs4286721 (P = 3.5 × 10−6), and IBD and KAT2A rs730086 (P = 2.3 × 10−6). Additional suggestive associations (P < 4.2 × 10−5) were observed between Crohn’s disease and IBD and African-specific SNPs in STAT5A and STAT3; between IBD and SNPs in IL23R, IL12B, and C2orf43; and between ulcerative colitis and SNPs near HDAC11 and near LINC00994. The latter 3 loci have not been previously associated with IBD, but require replication. Established Caucasian associations were replicated in AAs (P < 3.1 × 10−4) at NOD2, IL23R, 5p15.3, and IKZF3. Significant admixture (P < 3.9 × 10−4) was observed for 17q12−17q21.31 (IZKF3 through STAT3), 10q11.23−10q21.2, 15q22.2–15q23, and 16p12.2−16p12.1. Network analyses showed significant enrichment (false discovery rate <1 × 10−5) in genes that encode members of the JAK−STAT, cytokine, and chemokine signaling pathways, as well those involved in pathogenesis of measles. In a genetic analysis of 3308 AA IBD cases and controls, we found that many variants associated with IBD in Caucasians also showed association evidence with these diseases in AAs; we also found evidence for variants and loci not previously associated with IBD. The complex genetic factors that determine risk for or protection against IBD in different populations require further study.